Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
BUSINESS
Hisamitsu Initiates Japan PIII of Palmar Hyperhidrosis Drug, Aims at Filing in FY2022
Hisamitsu Pharmaceutical said on October 7 that it has initiated a Japanese PIII clinical trial of HP-5070 (oxybutynin HCl) for the treatment of primary palmar hyperhidrosis.The trial will investigate the efficacy and safety of HP-5070 compared to placebo, with the…
To read the full story
Related Article
BUSINESS
- Nipro Eyes 50-60 Stemirac Treatment Sites across Japan after Full Nod
November 20, 2026
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026





